Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00562380
Other study ID # AMGEN-479
Secondary ID CDR0000577404AMG
Status Completed
Phase Phase 1
First received November 21, 2007
Last updated July 17, 2013
Start date October 2005
Est. completion date June 2010

Study information

Verified date April 2010
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of AMG-479 in treating patients with advanced solid tumors or non-Hodgkin lymphoma.


Description:

OBJECTIVES:

Primary

- To assess the safety and pharmacokinetics of anti-IGF-1R fully human monoclonal antibody AMG-479 (AMG-479) after multiple intravenous administrations in adult patients with histologically documented advanced solid tumors that are refractory to standard therapy or for which no curative therapy is available.

Secondary

- To assess the tolerability and to determine the maximum tolerated dose of AMG-479.

- To assess tumor glucose metabolism using PET/CT scanning with the tracer fludeoxyglucose F 18.

- To measure insulin-like growth factor receptor (IGF-1R) levels on peripheral blood cells.

- To establish whether human anti-human antibodies to AMG-479 develop in patients with advanced solid tumors.

- To measure the tumor response by modified Response Evaluation Criteria in Solid Tumors.

Tertiary

- To investigate bone turnover markers.

- To investigate potential biomarker development by biochemical analysis in blood cells and tumor cells.

OUTLINE: This is a multicenter study.

- Part 1 (dose-escalation): Patients receive escalating doses of anti-IGF-1R fully human monoclonal antibody AMG-479 (AMG-479) IV over 1 hour on days 1, 15, and 29. Patients are evaluated in week 8, and those who demonstrate an objective tumor response or stable disease continue treatment beginning on day 57. Treatment with AMG-479 repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

- Part 2 (randomized dose-expansion): Patients are randomized to one of two dose regimens.

- Arm I: Patients receive AMG-479 IV over 1 hour at a lower dose on day 1.

- Arm II: Patients receive AMG-479 IV over 1 hour at a higher dose on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Tumor tissue is obtained at baseline and after 4 weeks of study therapy for biomarker analysis.

Blood is drawn periodically for biomarker analysis (insulin-like growth factor [IGF]-1, IGF-binding protein 3 [IGF-BP3], IGF-1 receptor [IGF-1R], cross-linked c-telopeptides of type 1 collagen [CTx], bone-specific alkaline phosphatase [BSAP], and tartrate-resistant acid phosphatase [TRAP5b]) and pharmacokinetic studies.

After completion of study therapy, patients are followed for at least 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date June 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

Inclusion criteria:

- Histologically or cytologically confirmed advanced solid tumors or non-Hodgkin lymphoma that is refractory to standard treatment or for which no curative therapy is available

- Tumor tissue that is accessible for biopsy by using minimally invasive procedures and must consent to undergo biopsies of the tumor (part 2)

- Exception for patients with Ewing family tumors or desmoplastic small round cell tumors whose anatomic location would pose an increase in the risk of injury due to biopsy (i.e., bleeding or pneumothorax)

- Willing to provide existing and/or future paraffin-embedded tumor samples

Exclusion criteria:

- Primary CNS tumors or hematological malignancies, other than non-Hodgkin lymphoma

- Primary hepatic tumors or at increased risk for hepatic tumors, including any of the following:

- Hepatitis of any etiology

- Alcohol abuse or dependency

- Hepatic adenoma

- Follicular nodular hyperplasia

- Autoimmune conditions associated with biliary tract cancer

- Alpha 1 antitrypsin deficiency

- Hemochromatosis

- History of vinyl chloride or thorotrast/thorium dioxide exposure

- History of histiocytic (Kupffer cell) neoplasia

- Presence of untreated or symptomatic CNS metastases or symptoms of brain metastases

- Presence of ascites or pleural effusion requiring medical intervention

PATIENT CHARACTERISTICS:

Inclusion criteria:

- ECOG performance status = 2

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Able to provide fasting blood samples for triglyceride and glucose laboratory tests

- Able to fast for 4-6 hours for fludeoxyglucose F18-PET/CT scan

- Controlled type 1 or 2 diabetes (defined as hemoglobin A1c < 8.0% and fasting blood glucose level < 160 mg/dL) allowed for part 2 only

Exclusion criteria:

- History of clinically significant hypoglycemia or hyperglycemia (in the opinion of the investigator)

- Myocardial infarction within the past year

- Unstable or uncontrolled disease/condition related to or impacting cardiac function, including any of the following:

- Unstable angina

- Congestive heart failure

- NYHA class III or IV heart disease

- Uncontrolled hypertension (diastolic BP > 90 mm Hg and systolic BP > 150 mm Hg)

- Clinically significant cardiac arrhythmia

- CTCAE version 3.0 = grade 2

- Clinically significant electrocardiogram abnormalities

- History of arterial or venous (deep vein) thrombosis within the past year

- History of bleeding diathesis

- History of chronic hepatitis

- History of HIV infection

- Unable to tolerate intravenous administration

- Known sensitivity to mammalian-derived products

- ANC < 1,500/mm^3 (without filgrastim [G-CSF] support within the past 2 weeks)

- Platelet count < 100,000/mm^3 (without transfusion within the past 2 weeks)

- Hemoglobin < 9 g/dL (without transfusion within the past 4 weeks)

- PT/PTT > 1.5 x upper limit of normal (ULN)

- Serum creatinine > 1.5 x ULN

- AST and ALT > 2.5 x ULN

- Total bilirubin > 1.5 x ULN

- Urinary protein excretion > 1,000 mg/day (= 2+ using dipstick analysis)

- Any kind of disorder that compromises the ability of the patient to give written informed consent and/or comply with study procedures

- Any comorbid medical condition, that in the sponsor's or investigator's opinion, may put the patients at significant risk

- Known sensitivity to any of the products to be administered during dosing

- Unresolved toxicities > grade 1 from prior anticancer therapy, excluding alopecia

PRIOR CONCURRENT THERAPY:

- No prior antitumor treatment within the past 28 days

- Palliative external-beam radiotherapy to a lesion not used for RECIST measurement is acceptable during study for symptom management if patient is stable or improving and not progressing

- At least 30 days since prior and no concurrent enrollment in another clinical trial involving medication

- No antibody therapy for the treatment of underlying malignancy within the past 8 weeks

- No concurrent or prior anticoagulation therapy, except low-dose warfarin (< 2 mg/day) for prophylaxis against central venous catheter thrombosis

- No concurrent insulin (except diabetic patients enrolled in dose expansion [part 2] of the study)

- No other concurrent investigational procedures

- No concurrent blood or blood-product transfusions

- No concurrent herbal medications

- No other concurrent anticancer therapy including chemotherapy or hormonal therapy

- Gonadotropic releasing-hormone agonists or antagonists allowed for advanced prostate cancer

- No major surgery within the past month and none planned for 28 days after completion of study treatment

Study Design

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
ganitumab

Other:
laboratory biomarker analysis

pharmacological study

Procedure:
biopsy


Locations

Country Name City State
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Amgen National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Yes
Primary Pharmacokinetic profile No
Secondary Level of insulin-like growth factor receptor-1 (IGF-1R) on peripheral blood cells No
Secondary Tumor response measured by modified RECIST No
Secondary Tumor glucose metabolism as measured by fludeoxyglucose F 18-PET/CT scan No
Secondary Anti-AMG-479 antibody formation No
Secondary The incidence of dose-limiting toxicities and the severity of adverse events Yes
Secondary Levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase (may also include tartrate-resistant acid phosphatase 5b) in blood No
Secondary Circulating levels of IGF-1R and IGF-BP3 No
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A